News
We send the latest information from SMC Laboratories.
Press Release Regarding STAM-HCC/IO+ Mice has been distributed.
We are pleased to announce that our STAM(TM)-HCC/IO+ mouse was introduced in PR Newswire (Kyodo News JBN). For details, please refer to the following URL. SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field URL ► https://kyodonewsprwire.jp/release/202402076294 …
Study published in Sci Transl Med. on the effects of A monoclonal antibody targeting nonjunctional claudin-1 in CKD of UUO model.
We introduce a case study of drug efficacy evaluation of anti-claudin-1 antibody using our chronic kidney disease model, UUO model. Title: A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity ( Roehlen et al., Sci Transl Med. 2022 ) Article Link ► [DOI: 10.1126/scitranslmed.abj4221] In this study, we administered…
Announcement of webinar 【MASH-Liver cancer model mouse_Pharmacology study for MASH/fibrosis targeting GLP-1】
Today, we are excited to invite you to join our Webinar that will be taking place on January 25th from 9:30 AM (JST). In this webinar, we will introduce the drug evaluation study with GLP-1. That is why we highly recommend that you join our free webinar! Webinar Link ►►► Click here …
MOA demonstration #1 【microbiota】| MASH treatment and fibrosis prevention study targeting gut microbiota in STAM mice
Today, we would like to introduce a demonstration example of a drug efficacy evaluation test of a bacterial consortium consisting of nine types of intestinal resident bacteria using STAMTM mouse (hereinafter “STAM mouse”), which was published in May 2022 in the journal Biomedicines by a research team from Belgium’s MRM Health. I would like to…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments that target fibrosis. Fibrosis is involved in many diseases, so even if fibrosis is not your direct target, please read on. Fibrosis can occur in many different organs. It is caused by a disruption in the wound healing…
Introduction of bleomycin-induced SSc-ILD model
Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop simultaneously. Systemic scleroderma is a progressive, rare disease that causes fibrosis not only in the skin but also in tissues throughout the body, including the heart, lungs and kidneys. Pulmonary disease is a complication that has…
STAM™ mice study: demonstration of MSCs-based cell therapy study for the NASH treatment
We introduce an example of a drug evaluation study on the efficacy of cell therapy in the treatment of NASH using our STAM™ mice, model of non-alcoholic steatohepatitis (NASH). Title: Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model ( Najimi et al., Cells. 2022 ) Article…
Study published in Cells. on the effects of ameliorating epigenetic modifications by ATP1A1 signalosome inhibition in the liver cancer of STAM™ mice
SMC is proud to announce that Marshall University (WV) has published the results of their study using our pre-clinical services with the STAM™ mice in Cells. Title: Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma (Rajan PK et al., Cells. 2023) Article Link ► [DOI: 10.3390/cells12192367] In this…
World COPD Day 2023 | “Breathing is Life – Act Earlier”
November 15th is World COPD Day, so why not learn more about COPD？ What is World COPD Day? World COPD Day was established by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to raise awareness, share knowledge, and discuss ways to reduce the burden of COPD worldwide. GOLD is a global organization promoting…
【New Preclinical Data】 The effects of Il-18 inhibitor on cholangitis and liver fibtrosis in DDC-induced primary sclerosing cholangitis (PSC) model mice
We are pleased to announce that our client AprilBio Co., Ltd. (KOR) published the results of preclinical studies of IL-18 inhibitor using our DDC-induced primary sclerosing cholangitis (PSC) mouse model in the journal Biomed Pharmacother. Title: Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease (Kim DH et al., Biomed…